Want to see JP:6039 full AI Analyst Report?
6039 Stock Chart & Stats
¥1175.00
-¥12.00(-0.51%)
At close: 4:00 PM EST
¥1175.00
-¥12.00(-0.51%)
Day’s Range― - ―
52-Week Range¥532.40 - ¥1,605.00
Previous CloseN/A
Volume1.40K
Average Volume (3M)24.65K
Market Cap
¥14.21B
Enterprise Value¥17.46B
Total Cash (Recent Filing)¥1.59B
Total Debt (Recent Filing)¥5.16B
Price to Earnings (P/E)15.4
Beta0.67
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.21%
Share Statistics
EPS (TTM)64.49
Shares Outstanding14,391,000
10 Day Avg. Volume16,500
30 Day Avg. Volume24,646
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)3.10
Price to Sales (P/S)2.44
P/FCF Ratio-15.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)77.4
Revenue Forecast (FY)¥6.70B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthMulti-year top-line expansion more than doubled revenue since FY2021 and continued 13% growth in FY2026. Durable revenue growth supports scalable referral hospital economics, strengthens bargaining with suppliers and partners, and underpins long-term investment in specialty services and capacity.
Improving Operating Cash GenerationConsistent and rising operating cash flow indicates core veterinary services are generating sustainable cash from operations. That provides flexibility to fund capex, working capital and service debt without relying solely on external financing, a durable strength for expansion of referral networks.
Balance-sheet Scale And ROE HistoryLarger asset base and rising equity provide structural capacity to support more complex, higher-acuity services. Historical ROE in the high single digits to low teens signals the business converts capital into returns, aiding sustainable reinvestment and credibility with lenders and referral partners.
Bears Say
Free Cash Flow VolatilityA large FCF swing reflects uneven conversion of operating cash into free cash, likely from heavy reinvestment or working-capital changes. Persistent FCF volatility reduces predictability for debt servicing, dividends or buybacks and raises execution risk for multi-year expansion plans.
Rising Debt In FY2026A material increase in borrowings in FY2026 reverses prior deleveraging and elevates leverage risk. Higher debt raises fixed charges and constrains financial flexibility, making the company more sensitive to adverse cash-flow swings and limiting capacity for opportunistic investment.
Variable Margins And Missing FY2026 DetailHistorical margin variability and lack of FY2026 margin disclosure increase uncertainty about profit sustainability as the company scales. If margins compress due to higher costs, pricing pressure from referrers, or mix shifts toward lower-acuity cases, earnings resilience could weaken over the medium term.
Japan Animal Referral Medical Center Co., Ltd. News
6039 FAQ
What was Japan Animal Referral Medical Center Co., Ltd.’s price range in the past 12 months?
Japan Animal Referral Medical Center Co., Ltd. lowest stock price was ¥532.40 and its highest was ¥1605.00 in the past 12 months.
What is Japan Animal Referral Medical Center Co., Ltd.’s market cap?
Japan Animal Referral Medical Center Co., Ltd.’s market cap is ¥14.21B.
When is Japan Animal Referral Medical Center Co., Ltd.’s upcoming earnings report date?
Japan Animal Referral Medical Center Co., Ltd.’s upcoming earnings report date is Aug 14, 2026 which is in 12 days.
How were Japan Animal Referral Medical Center Co., Ltd.’s earnings last quarter?
Japan Animal Referral Medical Center Co., Ltd. released its earnings results on May 15, 2026. The company reported ¥12.24 earnings per share for the quarter, beating the consensus estimate of N/A by ¥12.24.
Is Japan Animal Referral Medical Center Co., Ltd. overvalued?
According to Wall Street analysts Japan Animal Referral Medical Center Co., Ltd.’s price is currently Overvalued.
Does Japan Animal Referral Medical Center Co., Ltd. pay dividends?
Japan Animal Referral Medical Center Co., Ltd. pays a Annually dividend of ¥13 which represents an annual dividend yield of 1.21%. See more information on Japan Animal Referral Medical Center Co., Ltd. dividends here
What is Japan Animal Referral Medical Center Co., Ltd.’s EPS estimate?
Japan Animal Referral Medical Center Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Animal Referral Medical Center Co., Ltd. have?
Japan Animal Referral Medical Center Co., Ltd. has 14,391,000 shares outstanding.
What happened to Japan Animal Referral Medical Center Co., Ltd.’s price movement after its last earnings report?
Japan Animal Referral Medical Center Co., Ltd. reported an EPS of ¥12.24 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.135%.
Which hedge fund is a major shareholder of Japan Animal Referral Medical Center Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6039
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Animal Referral Medical Center Co., Ltd.
Japan Animal Referral Medical Center Co., Ltd. operates a network of animal medical facilities across Japan, specializing in delivering advanced veterinary care for dogs and cats. These comprehensive centers boast an extensive range of specialized departments, from cardiology, respiratory, urology, and gastroenterology to oncology, neurology, orthopedics, ophthalmology, diagnostic imaging, and anesthesiology. Beyond direct patient care, the company also offers professional training, encompassing clinical instruction and treatment practices. Furthermore, it actively engages in research and development initiatives, exploring fields such as genetic testing, immunotherapy, and regenerative medicine. The firm, established in 2005, has its headquarters located in Kawasaki, Japan.